Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: Design of a longitudinal clinical study

Cardiovascular Toxicology

Volumn 4, Issue 2, 2004, Pages 187-197

  Lavigne, Jill E ^a   Shearer, William T ^b   Thompson, Bruce ^c   Orav, E John ^d   Starc, Thomas J ^e   Colan, Steven D ^f   Pignatelli, Ricardo ^b   O'Brien, Sharon E ^h   Bezold, Louis ^b   LaRusa, Phillip ^e   Easley, Kirk A ^f   Cheng, Irene ^c   Duffy, Sarah A ^g   Lipshultz, Steven E ^g  

^a UNIVERSITY OF ROCHESTER   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c Clinical Trials & Surveys Corp   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Howard Hughes Medical Institute   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF MIAMI   (United States)

^h BOSTON MEDICAL CENTER   (United States)

Author keywords

Antiretroviral therapy; Cardiovascular; Highly active antiretroviral therapy; HIV; Mitochondria; Prophylaxis; Seroreverter; Study design; Toxicity; Vertical transmission

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; NATRIURETIC FACTOR; TROPONIN; ZIDOVUDINE;

ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CHILD; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FETUS; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MITOCHONDRIAL TOXICITY; OUTCOMES RESEARCH; PERINATAL DRUG EXPOSURE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SEROCONVERSION; SEROLOGY; VERTICAL TRANSMISSION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE TRANSMISSION, VERTICAL; ELECTROCARDIOGRAPHY; FEMALE; HEART DISEASES; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; INFANT; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 4744375732     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1385/CT:4:2:187     Document Type: Article

References (25)

1. The Data Collection on Adverse E vents of Anti-HIV Drugs (DAD) Study Group. (2003). Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349:1993-2003.
2. Fichtenbaum, C. (2003).http://www.hivandhepatitis.com/ 2003icr/EACS_9/pdf/Fichtenbaum%20-Embargoed%20 Until%20Presentation.pdf. Program and abstracts of the 9th European Conference on AIDS (9th EACS), Warsaw, Poland.
3. 2 HIV Study. Lancet 359:368-373.
4. Sklar, P. and Masur, H. (2003). HIV infection in cardiovascular disease - is there really a link? N. Engl. J. Med. 349:2065-2067.
5. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. AIDSinfo Website (http://AIDSinfo.nih.gov). December 2, 2003.
6. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV children. AIDSinfo Website (http://AIDSinfo.nih.gov). December 2, 2003.
7. Lipshultz, S.E. (2000). Ventricular dysfunction clinical research in infants, children and adolescents. Prog. Pediatr. Cardiol. 12:1-28.
8. Herman, E.H., Zhang, J., Rifai, N., Lipshultz, S.E., Hasinoff, B.B., Chadwick, D.P., et al. (2001). The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother. Pharmacol 48:297-304.
9. Herman, E.H., Zhang, J., Lipshultz, S.E., Rifai, N., Chadwick, O.P., Takeda, K., et al. (1999). Correlation between serum levels of cardiac troponin-T and the severity of chronic cardiomyopathy induced by doxorubicin. J. Clin. Oncol. 17:2237-2243.
10. Lipshultz, S.E., Rifai, N., Sallan, S.E., Lipsitz, S.R., Dalton, V., Sacks, D.B., et al. (1997). Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96:2641-2648.
11. Healey, J.S. and Smith, S.J. (2000). Prognostic value of serum troponin T and troponin I in heart failure. Paper presented at 51st Annual Scientific Session of the American College of Cardiology, March 17-20, 2002, Atlanta, GA.
12. Maisel, A.S., Krishnasamy, P., Koon, J., Garcia, A., Kazanegra, R., Gardetto, N., et al. (2000). A rapid bedside test for brain natriuretic peptide accurately delineates both systolic and diastolic dysfunction in patients referred for echocardiography. Paper presented at 51st Annual Scientific Session of the American College of Cardiology, March 17-20, 2002, Atlanta, GA.
13. Cowle, M.R.,Fox, K.F., Wood, D.A., Coats, A.J.S., Poole-Wilson, P.A., Thompson, S.G., et al. (2000). N-terminal Pro-BNP predicts prognosis in patients presenting with heart failure for the first time better than does N-terminal Pro-ANP or BNP. Paper presented at 51st Annual Scientific Session of the American College of Cardiology, March 17-20, 2002, Atlanta, GA.
14. Bettencourt, P., Ferreira, A., Dias, P., Castro, A., Martins, L., and Cerqueira-Gomes, M. (2000). Evaluation of brain natriuretic peptide in the diagnosis of heart failure. Cardiology 93:19-25.
15. Dries, D.L. and Stevenson, L.W. (2000). Brain natriuretic peptide as bridge to therapy for heart failure. Lancet 355: 1112-1113.
16. Dellargyris, E.N., Raymond, R.S., Theoharides, T.C., Pye, J.P., Boucher, W.S., and Dehmer, G.J. (2000). Elevated serum IL-6 levels in patients with asymptomatic left ventricular systolic dysfunction. Paper presented at 51st Annual Scientific Session of the American College of Cardiology, March 17-20, 2002, Atlanta, GA.
17. Roberts, W.L., Sedrick, R., Moulton, L., Spencer, A., and Rifai, N. (2000). Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin. Chem. 46:461-468.
18. 2 HIV) infection study: design and methods. J. Clin. Epidemiol. 49: 1285-1294.
19. Sheon, A.R., Fox, H.E., Rich, K.C., Stratton, P., Diaz, C., Tuomala, R., et al. (1996). The women and infants transmission study (WITS) of maternal-infant HIV transmission: study design, methods and baseline data. J. Women's Health 5:69-78.
20. 2 HIV Study Group. (1998). Prevalence of congenital cardiovascular malformations in children of human immunodeficiency virus-infected women. The prospective P2C2 HIV multicenter study. J. Am. Coll. Cardiol. 32:1749-1755.
21. 2 HIV Multicenter Study. Circulation 97; 1246-1256.
22. 2 HIV study. Circulation 104:310-316.
23. Lipshultz, S.E., Lipsitz, S.R., Sallan, S.E., Simbre, V.C. II, Shaikh, S.L., Mone, et al. (2002). Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J. Clin. Oncol. 20:4517-4522.
24. UNAIDS/WHO. (2003). Aids Epidemic Update. UNAIDS, Geneva, Switzerland.
25. World Health Organization. (2003). Treating Three Million by 2005: Making It Happen. World Health Organization, Geneva, Switzerland.